Multifaceted targeting in cancer: The recent cell death players meet the usual oncogene suspects

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 5, 2007, Pages 641-659

  Drosopoulos, Konstantinos ^a,b   Pintzas, Alexander ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b Breakthrough Breast Cancer Research Centre   (United Kingdom)

Author keywords

BCL 2; Death receptor; IAP; Oncogene; TRAIL

Indexed keywords

AEG 35156; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYTOCHROME C; CYTOTOXIC AGENT; E1A PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIGALLOCATECHIN GALLATE; FAS LIGAND; GOSSYPOL; IMATINIB; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LBW 242; LY 2181308; MYC PROTEIN; NEURONAL APOPTOSIS INHIBITORY PROTEIN; OBLIMERSEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN SERINE THREONINE KINASE; RAS PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SURVIVIN; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; GENE DELETION; GENE MUTATION; GENE TRANSFER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IN VIVO STUDY; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; NONVIRAL GENE THERAPY; ONCOGENE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; VIRAL GENE THERAPY; VIRUS TRANSFORMATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, KNOCKOUT; NEOPLASMS; ONCOGENE PROTEINS; ONCOGENES; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34248371111     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.5.641     Document Type: Review

References (215)

1. GRIFFITH TS, LYNCH DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol. (1998) 10:559-563.
2. DOVIO A, DATA V, ANGELI A: Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? J. Endocrinol. Invest. (2005) 28:14-22.
3. WADA T, NAKASHIMA T, HIROSHI N, PENNINGER JM: RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. (2006) 12:17-25.
4. ZERAFA N, WESTWOOD JA, CRETNEY E et al.: Cutting edge: TRAIL deficiency accelerates hematological malignancies. J. Immunol. (2005) 175:5586-5590.
5. CRETNEY E, TAKEDA K, YAGITA H, GLACCUM M, PESCHON JJ, SMYTH MJ: Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. (2002) 168:1356-1361.
6. EVANS CH: On the TRAIL of an arthritis cure. Gene Ther. (2004) 11:735-736.
7. -/- mice. Nat. Immunol. (2003) 4:255-260.
8. WALCZAK H, MILLER RE, ARIAIL K et al.: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. (1999) 5:157-163.
9. MIZUTANI Y, NAKANISHI H, YOSHIDA O, FUKUSHIMA M, BONAVIDA B, MIKI T: Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur. J. Cancer (2002) 38:167-176.
10. MARINI P, DENZINGER S, SCHILLER D et al.: Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene (2006) 25:5145-5154.
11. BREMER E, SAMPLONIUS DF, VAN GENNE L et al.: Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J. Biol. Chem. (2005) 280:10025-10033.
12. KOORNSTRA JJ, KLEIBEUKER JH, VAN GEELEN CM et al.: Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J. Pathol. (2003) 200:327-335.
13. STRATER J, HINZ U, WALCZAK H et al.: Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin. Cancer Res. (2002) 8:3734-3740.
14. DANIELS RA, TURLEY H, KIMBERLEY FC et al.: Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. (2005) 15:430-438.
15. MCCARTHY MM, SZNOL M, DIVITO KA, CAMP RL, RIMM DL, KLUGER HM: Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin. Cancer Res. (2005) 11:5188-5194.
16. HORAK P, PILS D, HALLER G et al.: Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol. Cancer Res. (2005) 3:335-343.
17. HOPKINS-DONALDSON S, ZIEGLER A, KURTZ S et al.: Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death. Differ. (2003) 10:356-364.
18. ADAMS J, CUTHBERT-HEAVENS D, BASS S, KNOWLES MA: Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity. Cancer Lett. (2005) 220:137-144.
19. LEE SH, SHIN MS, KIM HS et al.: Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. (1999) 59:5683-5686.
20. JENG YM, HSU HC: Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma. Cancer Lett. (2002) 181:205-208.
21. PARK WS, LEE JH, SHIN MS et al.: Inactivating mutations of KILLER/ DR5 gene in gastric cancers. Gastroenterology (2001) 121:1219-1225.
22. OZOREN N, FISHER MJ, KIM K et al.: Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int. J. Oncol. (2000) 16:917-925.
23. FISHER MJ, VIRMANI AK, WU L et al.: Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin. Cancer Res. (2001) 7:1688-1697.
24. DECHANT MJ, FELLENBERG J, SCHEUERPFLUG CG, EWERBECK V, DEBATIN KM: Mutation analysis of the apoptotic 'death-receptors' and the adaptors TRADD and FADD/MOAT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int. J. Cancer (2004) 109:661-667.
25. ARAI T, AKIYAMA Y, OKABE S, SAITO K, IWAI T, YUASA Y: Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas. Cancer Lett. (1998) 133:197-204.
26. SHIN MS, KIM HS, LEE SH et al.: Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. (2001) 61:4942-4946.
27. SHEIKH MS, HUANG Y, FERNANDEZ-SALAS EA et al.: The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene (1999) 18:4153-4159.
28. LEE HO, FERGUSON TA: Biology of FasL. Cytokine Growth Factor Rev. (2003) 14:325-335.
29. FRIESEN C, HERR I, KRAMMER PH, DEBATIN KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. (1996) 2:574-577.
30. MULLER M, STRAND S, HUG H et al.: Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. (1997) 99:403-413.
31. BREMER E, TEN CB, SAMPLONIUS DF, DE LEIJ LF, HELFRICH W: CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood (2006) 107:2863-2870.
32. SSOHOU-LUTY C, GERSPACH J, SIEGMUND D et al.: A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J. Mol. Med. (2006) 84:785-797.
33. ELOJEIMY S, MCKILLOP JC, EL-ZAWAHRY AM et al.: FasL gene therapy: a new therapeutic modality for head and neck cancer. Cancer Gene Ther. (2006) 13:739-745.
34. HOUSTON A, WALDRON-LYNCH FD, BENNETT MW et al.: Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo. Int. J. Cancer (2003) 107:209-214.
35. MOLLER P, KORETZ K, LEITHAUSER F et al.: Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer (1994) 57:371-377.
36. PEDUTO EL, GUILLOU L, SARAGA E et al.: Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas. Int. J. Cancer (1999) 81:772-778.
37. YAMANA K, BILIM V, HARA N et al.: Prognostic impact of FAS/CD95/ APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br. J. Cancer (2005) 93:544-551.
38. HALLERMALM K, DE GA, KIESSLING R, LEVITSKY V, LEVITSKAYA J: Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res. (2004) 64:6775-6782.
39. IGNEY FH, BEHRENS CK, KRAMMER PH: CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo. Int. J. Cancer (2005) 113:78-87.
40. RYAN AE, SHANAHAN F, O'CONNELL J, HOUSTON AM: Addressing the 'Fas counterattack' controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res. (2005) 65:9817-9823.
41. WOHLFART S, SEBINGER D, GRUBER P et al.: FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma. Am. J. Pathol. (2004) 164:1081-1089.
42. SHEN L, LIANG AC, LU L et al.: Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma. Am. J. Pathol. (2002) 161:2123-2131.
43. LANDOWSKI TH, QU N, BUYUKSAL I, PAINTER JS, DALTON WS: Mutations in the Fas antigen in patients with multiple myeloma. Blood (1997) 90:4266-4270.
44. TAMIYA S, ETOH K, SUZUSHIMA H, TAKATSUKI K, MATSUOKA M: Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood (1998) 91:3935-3942.
45. MUSCHEN M, RE D, BRAUNINGER A et al.: Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res. (2000) 60:5640-5643.
46. GRONBAEK K, STRATEN PT, RALFKIAER E et al.: Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood (1998) 92:3018-3024.
47. PETAK I, DANAM RP, TILLMAN DM et al.: Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death. Differ. (2003) 10:211-217.
48. ROTH W, ISENMANN S, NAKAMURA M et al.: Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. (2001) 61:2759-2765.
49. PITTI RM, MARSTERS SA, LAWRENCE DA et al.: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 396:699-703.
50. SHIN S, LEE Y, KIM W, KO H, CHOI H, KIM K: Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J. (2005) 24:3532-3542.
51. CORY S, HUANG DC, ADAMS JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene (2003) 22:8590-8607.
52. GOTTLIEB RA, GRANVILLE DJ: Analyzing mitochondrial changes during apoptosis. Methods (2002) 26:341-347.
53. HEISER D, LABI V, ERLACHER M, VILLUNGER A: The Bcl-2 protein family and its role in the development of neoplastic disease. Exp. Gerontol. (2004) 39:1125-1135.
54. KROEMER G, REED JC: Mitochondrial control of cell death. Nat. Med. (2000) 6:513-519.
55. FULDA S, DEBATIN KM: Exploiting death receptor signaling pathways for tumor therapy. Biochim. Biophys. Acta (2004) 1705:27-41.
56. HOFMANN WK, DE VS, TSUKASAKI K et al.: Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood (2001) 98:787-794.
57. TOURNEUR L, MISTOU S, MICHIELS FM et al.: Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene (2003) 22:2795-804.
58. NARAYAN G, PULIDO HA, KOUL S et al.: Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36. 3-q37.1 involved in cervical cancer progression. Oncogene (2003) 22:3489-3499.
59. RYU BK, LEE MG, CHI SC, KIM YW, PARK JH: Increased expression of cFLIP(L) in colonic adenocarcinoma. J. Pathol. (2001) 194:15-19.
60. RIPPO MR, MORETTI S, VESCOVI S et al.: FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene (2004) 23:7753-7760.
61. SCHIMMER AD, THOMAS MP, HURREN R et al.: Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res. (2006) 66:2367-2375.
62. PINGOUD-MEIER C, LANG D, JANSS AJ et al.: Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin. Cancer Res. (2003) 9:6401-6409.
63. ZUZAK TJ, STEINHOFF DF, SUTTON LN, PHILLIPS PC, EGGERT A, GROTZER MA: Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. Eur. J. Cancer (2002) 38:83-91.
64. LIU LX, LIU ZH, JIANG HC et al.: Profiling of differentially expressed genes in human gastric carcinoma by cDNA expression array. World J. Gastroenterol. (2002) 8:580-585.
65. KIM HS, LEE JW, SOUNG YH et al.: Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology (2003) 125:708-715.
66. SOUNG YH, LEE JW, KIM SY et al.: CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res. (2005) 65:815-821.
67. SOUNG YH, LEE JW, KIM SY et al.: Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. Oncogene (2005) 24:141-147.
68. DEVARAJAN E, SAHIN AA, CHEN JS et al.: Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene (2002) 21:8843-8851.
69. WINTER RN, KRAMER A, BORKOWSKI A, KYPRIANOU N: Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. (2001) 61:1227-1232.
70. THOMADAKI H, SCORILAS A: BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev. Clin. Lab Sci. (2006) 43:1-67.
71. BEDIKIAN AY, MILLWARD M, PEHAMBERGER H et al.: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. (2006) 24:4738-4745.
72. MOORE J, SEITER K, KOLITZ J et al.: A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk. Res. (2006) 30:777-783.
73. MITA MM, OCHOA L, ROWINSKY EK et al.: A Phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann. Oncol. (2006) 17:313-321.
74. GREEN DR, KROEMER G: Pharmacological manipulation of cell death: clinical applications in sight? J. Clin. Invest. (2005) 115:2610-2617.
75. LEE YK, BONE ND, STREGE AK, SHANAFELT TD, JELINEK DF, KAY NE: VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood (2004) 104:788-794.
76. VAN POZNAK C, SEIDMAN AD, REIDENBERG MM et al.: Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a Phase I/II clinical trial. Breast Cancer Res. Treat. (2001) 66:239-248.
77. LEI X, CHEN Y, DU G et al.: Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. FASEB J. (2006) 20:2147-2149.
78. XU L, YANG D, WANG S et al.: (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol. Cancer Ther. (2005) 4:197-205.
79. MOHAMMAD RM, WANG S, ABOUKAMEEL A et al.: Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol. Cancer Ther. (2005) 4:13-21.
80. CHAUHAN D, NERI P, VELANKAR M et al.: Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood (2007) 109:1220-1227.
81. SCHIMMER AD: Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. (2004) 64:7183-7190.
82. NI T, LI W, ZOU F: The ubiquitin ligase ability of IAPs regulates apoptosis. IUBMB. Life (2005) 57:779-785.
83. HUANG Y, PARK YC, RICH RL, SEGAL D, MYSZKA DG, WU H: Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell (2001) 104:781-790.
84. SCHIMMER AD, DALILI S, BATEY RA, RIEDL SJ: Targeting XIAP for the treatment of malignancy. Cell Death. Differ. (2006) 13:179-188.
85. MORIZANE Y, HONDA R, FUKAMI K, YASUDA H: X-linked inhibitor of apoptosis functions as ubiquitin ligase toward mature caspase-9 and cytosolic Smac/ DIABLO. J. Biochem. (Tokyo) (2005) 137:125-132.
86. HU S, YANG X: Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. J. Biol. Chem. (2003) 278:10055-10060.
87. FU J, JIN Y, AREND LJ: Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-inhibiting activity of X-linked inhibitor of apoptosis protein. J. Biol. Chem. (2003) 278:52660-52672.
88. YANG QH, DU C: Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. J. Biol. Chem. (2004) 279:16963-16970.
89. CREAGH EM, MURPHY BM, DURIEZ PJ, DUCKETT CS, MARTIN SJ: Smac/Diablo antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins. J. Biol. Chem. (2004) 279:26906-26914.
90. DOHI T, OKADA K, Xia F et al.: An IAP-IAP complex inhibits apoptosis. J. Biol. Chem. (2004) 279:34087-34090.
91. MARUSAWA H, MATSUZAWA S, WELSH K et al.: HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. (2003) 22:2729-2740.
92. COLNAGHI R, CONNELL CM, BARRETT RM, WHEATLEY SP: Separating the anti-apoptotic and mitotic roles of survivin. J. Biol. Chem. (2006) 281:33450-33456.
93. CALDAS H, JIANG Y, HOLLOWAY MP et al.: Survivin splice variants regulate the balance between proliferation and cell death. Oncogene (2005) 24:1994-2007.
94. ZHU N, GU L, FINDLEY HW, LI F, ZHOU M: An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene (2004) 23:7545-7551.
95. WEIKERT S, SCHRADER M, CHRISTOPH F et al.: Quantification of survivin mRNA in testes of infertile patients and in testicular germ cell tumours: high levels of expression associated with normal spermatogenesis. Int. J. Androl. (2005) 28:224-229.
96. WEIKERT S, SCHRADER M, KRAUSE H, SCHULZE W, MULLER M, MILLER K: The inhibitor of apoptosis (IAP) survivin is expressed in human testicular germ cell tumors and normal testes. Cancer Lett. (2005) 223:331-337.
97. CHAWLA-SARKAR M, BAE SI, REU FJ, JACOBS BS, LINDNER DJ, BORDEN EC: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death. Differ. (2004) 11:915-923.
98. ASANUMA K, TSUJI N, ENDOH T, YAGIHASHI A, WATANABE N: Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells. J. Immunol. (2004) 172:3922-3929.
99. CONWAY EM, POLLEFEYT S, STEINER-MOSONYI M et al.: Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology (2002) 123:619-631.
100. SARELA AI, MACADAM RC, FARMERY SM, MARKHAM AF, GUILLOU PJ: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut (2000) 46:645-650.
101. BOMAN BM, WALTERS R, FIELDS JZ et al.: Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population. Am. J. Pathol. (2004) 165:1489-1498.
102. KENNEDY SM, O'DRISCOLL L, PURCELL R et al.: Prognostic importance of survivin in breast cancer. Br. J. Cancer (2003) 88:1077-1083.
103. O'DRISCOLL L, LINEHAN R, KENNEDY M et al.: Lack of prognostic significance of survivin, survivin-δEx3, survivin-2B, galectin-3, bag-1, bax-α and MRP-1 mRNAs in breast cancer. Cancer Lett. (2003) 201:225-236.
104. GRAAF AO, HAN VAN KRIEKEN J, TONNISSEN E et al.: Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br. J. Haematol. (2005) 130:852-859.
105. FERRANDINA G, LEGGE F, MARTINELLI E et al.: Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br. J. Cancer (2005) 92:271-277.
106. WU M, YUAN S, SZPORN AH, GAN L, SHTILBANS V, BURSTEIN DE: Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod. Pathol. (2005) 18:1618-1622.
107. YAN Y, MAHOTKA C, HEIKAUS S et al.: Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br. J. Cancer (2004) 91:1349-1357.
108. TAMM I, KORNBLAU SM, SEGALL H et al.: Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. (2000) 6:1796-803.
109. BEREZOVSKAYA O, SCHIMMER AD, GLINSKII AB et al.: Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. (2005) 65:2378-2386.
110. TAKEUCHI H, KIM J, FUJIMOTO A et al.: X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. Clin. Cancer Res. (2005) 11:7621-7628.
111. LACASSE EC, CHERTON-HORVAT GG, HEWITT KE et al.: Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin. Cancer Res. (2006) 12:5231-5241.
112. LACASSE EC, KANDIMALLA ER, WINOCOUR P et al.: Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/GEM640. Ann. N. Y. Acad. Sci. (2005) 1058:215-234.
113. KIM DK, ALVARADO CS, ABRAMOWSKY CR et al.: Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr. Dev. Pathol. (2005) 8:621-629.
114. YAGIHASHI A, OHMURA T, ASANUMA K et al.: Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin. Chim. Acta (2005) 362:125-130.
115. IMOTO I, TSUDA H, HIRASAWA A et al.: Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res. (2002) 62:4860-4866.
116. DAI Z, ZHU WC, MORRISON CD et al.: A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum. Mol. Genet. (2003) 12:791-801.
117. IMOTO I, YANG ZQ, PIMKHAOKHAM A et al.: Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res. (2001) 61:6629-6634.
118. TANIMOTO T, TSUDA H, IMAZEKI N et al.: Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomas. Cancer Lett. (2005) 224:141-151.
119. KRAJEWSKA M, KIM H, KIM C et al.: Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin. Cancer Res. (2005) 11:5451-5461.
120. DURKOP H, HIRSCH B, HAHN C, STEIN H: cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3. J. Mol. Med. (2006) 84:132-141.
121. HASEGAWA T, SUZUKI K, SAKAMOTO C et al.: Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. Blood (2003) 101:1164-1171.
122. EVAN GI, WYLLIE AH, GILBERT CS et al.: Induction of apoptosis in fibroblasts by c-myc protein. Cell (1992) 69:119-128.
123. WANG Y, ENGELS IH, KNEE DA, NASOFF M, DEVERAUX QL, QUON KC: Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell (2004) 5:501-512.
124. ROTTMANN S, WANG Y, NASOFF M, DEVERAUX QL, QUON KC: A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3β/FBW7 loss of function. Proc. Natl. Acad. Sci. USA (2005) 102:15195-15200.
125. RICCI MS, JIN Z, DEWS M et al.: Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell Biol. (2004) 24:8541-8555.
126. SHIIO Y, SUH KS, LEE H, YUSPA SH, EISENMAN RN, AEBERSOLD R: Quantitative proteomic analysis of myc-induced apoptosis: a direct role for Myc induction of the mitochondrial chloride ion channel, mtCLIC/CLIC4. J. Biol. Chem. (2006) 281:2750-2756.
127. DANG CV, O'DONNELL KA, JUOPPERI T: The great MYC escape in tumorigenesis. Cancer Cell (2005) 8:177-178.
128. CUI H, LI T, DING HF: Linking of N-Myc to death receptor machinery in neuroblastoma cells. J. Biol. Chem. (2005) 280:9474-9481.
129. TEITZ T, WEI T, VALENTINE MB et al.: Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. (2000) 6:529-535.
130. HARADA K, TOYOOKA S, SHIVAPURKAR N et al.: Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. (2002) 62:5897-901.
131. FULDA S, KUFER MU, MEYER E, VAN VALEN F, DOCKHORN-DWORNICZAK B, DEBATIN KM: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene (2001) 20:5865-5877.
132. ROBERTS ML, DROSOPOULOS KG, VASILEIOU I et al.: Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line. Int. J. Cancer (2006) 118:616-627.
133. HANCOCK JF: Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell Biol. (2003) 4:373-384.
134. PELI J, SCHROTER M, RUDAZ C et al.: Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J. (1999) 18:1824-1831.
135. SOMMER KW, SCHAMBERGER CJ, SCHMIDT GE, SASGARY S, CERNI C: Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene (2003) 22:4266-4280.
136. LIU Z, LI H, DEROUET M et al.: ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. J. Biol. Chem. (2005) 280:37383-37392.
137. BYUN DS, CHO K, RYU BK et al.: Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13. 2 locus, in human gastric adenocarcinomas. Cancer Res. (2003) 63:7068-7075.
138. DROSOPOULOS KG, ROBERTS ML, CERMAK L et al.: Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J. Biol. Chem. (2005) 280:22856-22867.
139. NESTEROV A, NIKRAD M, JOHNSON T, KRAFT AS: Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-α-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. (2004) 64:3922-3927.
140. VOS MD, DALLOL A, ECKFELD K et al.: The RASSF1A tumor suppressor activates Bax via MOAP-1. J. Biol. Chem. (2006) 281:4557-4563.
141. BAKSH S, TOMMASI S, FENTON S et al.: The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol. Cell (2005) 18:637-650.
142. BIVONA TG, QUATELA SE, BODEMANN BO et al.: PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol. Cell (2006) 21:481-493.
143. LIU X, YUE P, KHURI FR, SUN SY: p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. (2004) 64:5078-5083.
144. TAKIMOTO R, EL-DEIRY WS: Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene (2000) 19:1735-1743.
145. SAX JK, FEI P, MURPHY ME, BERNHARD E, KORSMEYER SJ, EL-DEIRY WS: BID regulation by p53 contributes to chemosensitivity. Nat. Cell Biol. (2002) 4:842-849.
146. MIYASHITA T, REED JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 80:293-299.
147. RIES S, BIEDERER C, WOODS D et al.: Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell (2000) 103:321-330.
148. HALASCHEK-WIENER J, WACHECK V, KLOOG Y, JANSEN B: Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells. Cell Signal. (2004) 16:1319-1327.
149. ZHANG Z, WANG H, LI M, RAYBURN ER, AGRAWAL S, ZHANG R: Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene (2005) 24:7238-7247.
150. BI B, LITTLEWOOD NK, CRISPE IN: Cleavage of E2F-1-regulating proteins and activation of E2F-1 during CD95-induced death of thymocytes. Immunology (2001) 104:37-42.
151. LIEMAN JH, WORLEY LA, HARBOUR JW: Loss of Rb-E2F repression results in caspase-8-mediated apoptosis through inactivation of focal adhesion kinase. J. Biol. Chem. (2005) 280:10484-10490.
152. CAO Q, XIA Y, AZADNIV M, CRISPE IN: The E2F-1 transcription factor promotes caspase-8 and bid expression, and enhances Fas signaling in T cells. J. Immunol. (2004) 173:1111-1117.
153. MORONI MC, HICKMAN ES, LAZZERINI DE et al.: Apaf-1 is a transcriptional target for E2F and p53. Nat. Cell Biol. (2001) 3:552-558.
154. NAHLE Z, POLAKOFF J, DAVULURI RV et al.: Direct coupling of the cell cycle and cell death machinery by E2F. Nat. Cell Biol. (2002) 4:859-864.
155. LEE EY, CHANG CY, HUN et al.: Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature (1992) 359:288-294.
156. IKENOUE T, KANAI F, HIKIBA Y et al.: Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. (2005) 65:4562-4567.
157. ISAKOFF SJ, ENGELMAN JA, IRIE HY et al.: Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. (2005) 65:10992-11000.
158. PHILLIPS WA, RUSSELL SE, CIAVARELLA ML et al.: Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int. J. Cancer (2006) 118:2644-2666.
159. GARCIA-ROSTAN G, COSTA AM, PEREIRA-CASTRO I et al.: Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. (2005) 65:10199-10207.
160. OSAKI M, OSHIMURA M, ITO H: PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis (2004) 9:667-676.
161. KANDASAMY K, SRIVASTAVA RK: Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res. (2002) 62:4929-4937.
162. MAJEWSKI N, NOGUEIRA V, ROBEY RB, HAY N: Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol. Cell Biol. (2004) 24:730-740.
163. PANNER A, JAMES CD, BERGER MS, PIEPER RO: mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol. Cell Biol. (2005) 25:8809-8823.
164. PANNER A, PARSA AT, PIEPER RO: Translational regulation of TRAIL sensitivity. Cell Cycle (2006) 5:147-150.
165. URIARTE SM, JOSHI-BARVE S, SONG Z et al.: Akt inhibition upregulates FasL, downregulates c-FLIPs and induces caspase-8-dependent cell death in Jurkat T lymphocytes. Cell Death. Differ. (2005) 12:233-242.
166. QI XJ, WILDEY GM, HOWE PH: Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J. Biol. Chem. (2006) 281:813-823.
167. SHE QB, SOLIT DB, YE Q, O'REILLY KE, LOBO J, ROSEN N: The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell (2005) 8:287-297.
168. DEL PESO L, GONZALEZ-GARCIA M, PAGE C, HERRERA R, NUNEZ G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (1997) 278:687-689.
169. SEMBA S, TRAPASSO F, FABBRI M et al.: Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene (2006) 25:2860-2872.
170. ASANUMA H, TORIGOE T, KAMIGUCHI K et al.: Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/ AKT signaling pathway in breast cancer cells. Cancer Res. (2005) 65:11018-11025.
171. DAN HC, SUN M, KANEKO S et al.: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. (2004) 279:5405-5412.
172. IVANOV VN, KRASILNIKOV M, RONAI Z: Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling. J. Biol. Chem. (2002) 277:4932-4944.
173. SEMBA K, KAMATA N, TOYOSHIMA K, YAMAMOTO T: A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc. Natl. Acad. Sci. USA (1985) 82:6497-501.
174. KING CR, KRAUS MH, AARONSON SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science (1985) 229:974-976.
175. FUJIMOTO N, WISLEZ M, ZHANG J et al.: High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res. (2005) 65:11478-11485.
176. CUELLO M, ETTENBERG SA, CLARK AS et al.: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. (2001) 61:4892-900.
177. KIM KM, LEE YJ: Role of HER-2/neu signaling in sensitivity to tumor necrosis factor-related apoptosis-inducing ligand: enhancement of TRAIL-mediated apoptosis by amiloride. J. Cell Biochem. (2005) 96:376-389.
178. NAGATA Y, LAN KH, ZHOU X et al.: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 6:117-127.
179. ZHOU BP, LIAO Y, XIA W, ZOU Y, SPOHN B, HUNG MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. (2001) 3:973-982.
180. DUBSKA L, ANDERA L, SHEARD MA: HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. FEBS Lett. (2005) 579:4149-4158.
181. SHTIVELMAN E, LIFSHITZ B, GALE RP, CANAANI E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (1985) 315:550-554.
182. ROWLEY JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 243:290-293.
183. SHAH NP, TRAN C, LEE FY, CHEN P, NORRIS D, SAWYERS CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305:399-401.
184. CONTE E, STAGNO F, GUGLIELMO P, SCUTO A, CONSOLI C, MESSINA A: Survivin expression in chronic myeloid leukemia. Cancer Lett. (2005) 225:105-110.
185. CARTER BZ, MAK DH, SCHOBER WD et al.: Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood (2006) 107:1555-1563.
186. WANG Z, SAMPATH J, FUKUDA S, PELUS LM: Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. (2005) 65:8224-8232.
187. UNO K, INUKAI T, KAYAGAKI N et al.: TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood (2003) 101:3658-3667.
188. + progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia (2005) 19:1034-1041.
189. GHAFFARI S, JAGANI Z, KITIDIS C, LODISH HF, KHOSRAVI-FAR R: Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc. Natl. Acad. Sci. USA (2003) 100:6523-6528.
190. NIMMANAPALLI R, POROSNICU M, NGUYEN D et al.: Cotreatment with STI-571 enhances tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin. Cancer Res. (2001) 7:350-357.
191. HAO JH, YU M, LIU FT, NEWLAND AC, JIA L: Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res. (2004) 64:3607-3616.
192. NIMMANAPALLI R, O'BRYAN E, HUANG M et al.: Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. (2002) 62:5761-5769.
193. GUO F, SIGUA C, BALI P et al.: Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood (2005) 105:1246-1255.
194. HELT AM, GALLOWAY DA: Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis (2003) 24:159-169.
195. ZHU H, LING W, HUB et al.: Adenovirus E1A reverses the resistance of normal primary human lung fibroblast cells to TRAIL through DR5 upregulation and caspase 8-dependent pathway. Cancer Biol. Ther. (2006) 5:180-188.
196. SHAO R, LEE DF, WEN Y et al.: E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation. Mol. Cancer Res. (2005) 3:219-226.
197. ROUTES JM, RYAN S, CLASE A et al.: Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J. Immunol. (2000) 165:4522-4527.
198. FLINTERMAN M, GUELEN L, EZZATI-NIK S et al.: E1A activates transcription of p73 and Noxa to induce apoptosis. J. Biol. Chem. (2005) 280:5945-5959.
199. SONG S, WIENTJES MG, GAN Y, AU JL: Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc. Natl. Acad Sci. USA (2000) 97:8658-8663.
200. PARDO OE, ARCARO A, SALERNO G, RAGUZ S, DOWNWARD J, SECKL MJ: Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J. Biol. Chem. (2002) 277:12040-12046.
201. PARDO OE, LESAY A, ARCARO A et al.: Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol. Cell Biol. (2003) 23:7600-7610.
202. EVES EM, SKOCZYLAS C, YOSHIDA K, ALNEMRI ES, ROSNER MR: FGF induces a switch in death receptor pathways in neuronal cells. J. Neurosci. (2001) 21:4996-5006.
203. CHOI EA, LEI H, MARON DJ et al.: Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon β in human cancer cells. Cancer Res. (2003) 63:5299-5307.
204. LARRIBERE L, KHALED M, TARTARE-DECKERT S et al.: PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death. Differ. (2004) 11:1084-1091.
205. LOBERG RD, GAYED BA, OLSON KB, PIENTA KJ: A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. J. Cell Biochem. (2005) 96:439-446.
206. + cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood (2001) 97:3075-3085.
207. ABDOLLAHI T, ROBERTSON NM, ABDOLLAHI A, LITWACK G: Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells. Apoptosis (2005) 10:1383-1393.
208. YUAN H, LIDDLE FJ, MAHAJAN S, FRANK DA: IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor. Carcinogenesis (2004) 25:2247-2255.
209. DIETEL M, SERS C: Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch. (2006) 448:744-755.
210. PUSZTAI L, MAZOUNI C, ANDERSON K, WU Y, SYMMANS WF: Molecular classification of breast cancer: limitations and potential. Oncologist (2006) 11:868-877.
211. BILD AH, YAO G, CHANG JT et al.: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2006) 439:353-357.
212. AXELROD R, AXELROD DE, PIENTA KJ: Evolution of cooperation among tumor cells. Proc. Natl. Acad. Sci. USA (2006) 103:13474-13469.
213. SAWYERS C: Targeted cancer therapy. Nature (2004) 432:294-297.
214. OIKONOMOU E, PINTZAS A: Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies. Anti-Cancer Res. (2006) 26:1077-1084.
215. BYKOV VJ, ISSAEVA N, SHILOV A et al.: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. (2002) 8:282-288.